The Effects of a Novel Calcium-Free Lactate Buffered Dialysis and Substitution Fluid for Regional Citrate Anticoagulation - Prospective Feasibility Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10293142" target="_blank" >RIV/00216208:11110/14:10293142 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/14:10293142

Výsledek na webu

<a href="http://dx.doi.org/10.1159/000369956" target="_blank" >http://dx.doi.org/10.1159/000369956</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000369956" target="_blank" >10.1159/000369956</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Effects of a Novel Calcium-Free Lactate Buffered Dialysis and Substitution Fluid for Regional Citrate Anticoagulation - Prospective Feasibility Study

Popis výsledku v původním jazyce

Background: Testing metabolic effects of a novel calcium-free, magnesium, phosphate and lactate containing solution (Lactocitrate) in combination with citrate anticoagulation. Methods: Patients on CRRT (2,000 ml/h, blood flow (Qb) 100 ml/min, trisodium citrate (4% TSC)) with arterial lactate <3 mmol/l were included. At start, bicarbonate-buffered fluid was changed to Lactocitrate and the substitution of magnesium and phosphorus ceased. At 9 h the Qb was increased to 150 ml/min. At 18 h the CRRT dosage was increased to 3,000 ml/h. Results: In 22 CVVHDF patients and another 23 on CVVH the pH, aHCO 3 and Na (all p > 0.05) showed no significant changes regardless of the increased dosage of 4% TSC at 9 h (p < 0.001). Mg tot and phosphorus stabilised withinnormal range. Arterial lactate increased to 1.9 (1.6-2.6) mmol/l at 3,000 ml/h, p < 0.001). Citrate-and lactate-related energetic gains were up to 74 (61-86) kJ/h. Conclusions: The fluid performed well within ordinary CRRT dosage and Qb u

Název v anglickém jazyce

The Effects of a Novel Calcium-Free Lactate Buffered Dialysis and Substitution Fluid for Regional Citrate Anticoagulation - Prospective Feasibility Study

Popis výsledku anglicky

Background: Testing metabolic effects of a novel calcium-free, magnesium, phosphate and lactate containing solution (Lactocitrate) in combination with citrate anticoagulation. Methods: Patients on CRRT (2,000 ml/h, blood flow (Qb) 100 ml/min, trisodium citrate (4% TSC)) with arterial lactate <3 mmol/l were included. At start, bicarbonate-buffered fluid was changed to Lactocitrate and the substitution of magnesium and phosphorus ceased. At 9 h the Qb was increased to 150 ml/min. At 18 h the CRRT dosage was increased to 3,000 ml/h. Results: In 22 CVVHDF patients and another 23 on CVVH the pH, aHCO 3 and Na (all p > 0.05) showed no significant changes regardless of the increased dosage of 4% TSC at 9 h (p < 0.001). Mg tot and phosphorus stabilised withinnormal range. Arterial lactate increased to 1.9 (1.6-2.6) mmol/l at 3,000 ml/h, p < 0.001). Citrate-and lactate-related energetic gains were up to 74 (61-86) kJ/h. Conclusions: The fluid performed well within ordinary CRRT dosage and Qb u

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood Purification

ISSN

0253-5068

e-ISSN

—

Svazek periodika

38

Číslo periodika v rámci svazku

3-4

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

10

Strana od-do

263-272

Kód UT WoS článku

000349638200016

EID výsledku v databázi Scopus

—